5F-JWH-398 |
|
(4-Chloronaphthalen-1-yl)-[1-(5-fluoropentyl)indol-3-yl]methanone
|
| CAS Number | |
|---|
| PubChem CID | |
|---|
| ChemSpider | |
|---|
| UNII | |
|---|
| CompTox Dashboard (EPA) | |
|---|
|
| Formula | C24H21ClFNO |
|---|
| Molar mass | 393.89 g·mol−1 |
|---|
| 3D model (JSmol) | |
|---|
Clc1ccc(c2ccccc21)C(=O)c1cn(CCCCCF)c2ccccc21
|
InChI=1S/C24H21ClFNO/c25-22-13-12-20(17-8-2-3-9-18(17)22)24(28)21-16-27(15-7-1-6-14-26)23-11-5-4-10-19(21)23/h2-5,8-13,16H,1,6-7,14-15H2 Key:MJSLVWWUOKKZTQ-UHFFFAOYSA-N
|
5F-JWH-398 (4'-chloro-AM-2201, Cl-2201, CLAM, SGT-20) is a recreational designer drug which is classed as a synthetic cannabinoid. It is from the naphthoylindole family, and produces cannabis-like effects. It was legally sold in New Zealand from 2012 to 2014 under the psychoactive substances scheme but was discontinued in May 2014 following the end of the interim approval period under the Psychoactive Substances Act 2013.[1][2][3] Subsequently, it has appeared on the illicit market around the world and was identified in Germany in May 2019.[4]
See also
References
|
|---|
Phytocannabinoids (comparison) | | Cannabibutols | |
|---|
| Cannabichromenes | |
|---|
| Cannabicyclols | |
|---|
| Cannabidiols | |
|---|
| Cannabielsoins | |
|---|
| Cannabigerols | |
|---|
| Cannabiphorols | |
|---|
| Cannabinols |
- CBN
- CBNA
- CBN-C1
- CBN-C2
- CBN-C4
- CBNM
- CBND
- CBNP
- CBVD
|
|---|
| Cannabitriols | |
|---|
| Cannabivarins | |
|---|
| Delta-3-tetrahydrocannabinols | |
|---|
| Delta-4-tetrahydrocannabinols | |
|---|
| Delta-7-tetrahydrocannabinols | |
|---|
| Delta-8-tetrahydrocannabinols | |
|---|
| Delta-9-tetrahydrocannabinols | |
|---|
| Delta-10-Tetrahydrocannabinols | |
|---|
| Delta-11-Tetrahydrocannabinols | |
|---|
| Miscellaneous cannabinoids | |
|---|
| Active metabolites | |
|---|
|
|---|
| Endocannabinoids | |
|---|
Synthetic cannabinoid receptor agonists / neocannabinoids | Classical cannabinoids (dibenzopyrans) | |
|---|
Non-classical cannabinoids | |
|---|
| Adamantoylindoles | |
|---|
| Benzimidazoles | |
|---|
| Benzoylindoles |
- 1-Butyl-3-(2-methoxybenzoyl)indole
- 1-Butyl-3-(4-methoxybenzoyl)indole
- 1-Pentyl-3-(2-methoxybenzoyl)indole
- AM-630
- AM-679
- AM-694
- AM-1241
- AM-2233
- GW-405,833 (L-768,242)
- Pravadoline
- RCS-4
- WIN 54,461
|
|---|
| Cyclohexylphenols | |
|---|
| Eicosanoids |
- AM-883
- AM-1346
- ACEA
- ACPA
- Methanandamide (AM-356)
- O-585
- O-689
- O-1812
- O-1860
- O-1861
|
|---|
Indazole-3- carboxamides | |
|---|
| Indole-3-carboxamides | |
|---|
| Indole-3-carboxylates | |
|---|
| Naphthoylindazoles | |
|---|
| Naphthoylindoles | |
|---|
| Naphthoylpyrroles |
- JWH-030
- JWH-031
- JWH-032
- JWH-033
- JWH-036
- JWH-044
- JWH-045
- JWH-145
- JWH-146
- JWH-147
- JWH-150
- JWH-156
- JWH-243
- JWH-244
- JWH-245
- JWH-246
- JWH-292
- JWH-293
- JWH-307
- JWH-308
- JWH-309
- JWH-346
- JWH-347
- JWH-348
- JWH-363
- JWH-364
- JWH-365
- JWH-366
- JWH-367
- JWH-368
- JWH-369
- JWH-370
- JWH-371
- JWH-372
- JWH-373
|
|---|
| Naphthylmethylindenes | |
|---|
| Naphthylmethylindoles |
- JWH-175
- JWH-184
- JWH-185
- JWH-192
- JWH-194
- JWH-195
- JWH-196
- JWH-197
- JWH-199
|
|---|
| Phenylacetylindoles | |
|---|
| Pyrazolecarboxamides | |
|---|
Tetramethylcyclo- propanoylindazoles | |
|---|
Tetramethylcyclo- propanoylindoles | |
|---|
| Others | |
|---|
|
|---|
| Allosteric CBRTooltip Cannabinoid receptor ligands | |
|---|
Endocannabinoid enhancers (inactivation inhibitors) | |
|---|
Anticannabinoids (antagonists/inverse agonists/antibodies) | |
|---|
|
|
|---|
Receptor (ligands) | | CB1Tooltip Cannabinoid receptor type 1 | Agonists (abridged, full list) | |
|---|
| Inverse agonists | |
|---|
| Antagonists | |
|---|
|
|---|
| CB2Tooltip Cannabinoid receptor type 2 | | Agonists |
- 2-AG
- 2-AGE (noladin ether)
- 3,3'-Diindolylmethane
- 4-O-Methylhonokiol
- α-Amyrin · β-Amyrin
- A-796,260
- A-834,735
- A-836,339
- AM-1172
- AM-1221
- AM-1235
- AM-1241
- AM-2232
- Anandamide
- AZ-11713908
- Cannabinol
- Caryophyllene
- CB-13
- CBS-0550
- CP 55,940
- GW-405,833 (L-768,242)
- GW-842,166X
- HU-308
- JTE 7-31
- JWH-007
- JWH-015
- JWH-018
- JWH-73
- JWH-133
- L-759,633
- L-759,656
- Lenabasum (anabasum)
- Magnolol
- MDA-19
- Nabitan
- NADA
- Olorinab (APD-371)
- PF-03550096
- S-444,823
- SER-601
- Serinolamide A
- UR-144
- Tedalinab
- THC (dronabinol)
- THCV
- Tetrahydromagnolol
- Virodhamine
|
|---|
| Antagonists | |
|---|
|
|---|
NAGly (GPR18) | |
|---|
| GPR55 | |
|---|
| GPR119 | |
|---|
|
|---|
Transporter (modulators) | | eCBTsTooltip Endocannabinoid transporter | |
|---|
|
|---|
Enzyme (modulators) | | FAAHTooltip Fatty acid amide hydrolase | |
|---|
| MAGL | |
|---|
| ABHD6 |
- Inhibitors: JZP-169
- JZP-430
- KT182
- KT185
- KT195
- KT203
- LEI-106
- ML294
- ML295
- ML296
- UCM710
- WWL-70
|
|---|
| ABHD12 | |
|---|
|
|---|
| Others |
- Precursors: Phosphatidylethanolamine
- NAPE
- Diacylglycerol
- Others: 2-PG (directly potentiates activity of 2-AG at CB1 receptor)
- ARN-272 (FAAH-like anandamide transporter inhibitor)
|
|---|
- See also
- Receptor/signaling modulators
- Cannabinoids (cannabinoids by structure)
|